Ribomic, Inc. (4591) Press Release
Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2026(Based on Japanese GAAP)
Earlier from Ribomic
- RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
- RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older
- RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort
- RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study